Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

As many as 17% of men and 34% of women in the United States suffer from sleep apnea, and the numbers are increasing. KYW ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists, or GLP-1.

However, unlike Mounjaro and Ozempic, Zepbound is FDA approved for weight loss in adults when combined with diet and lifestyle changes. While research is ongoing, a landmark 2022 study of more ...

Lilly’s weekly Zepbound is the frontrunner among obesity treatments on the market — helping patients lose an average of 20.2% of their body weight over a 72-week period. However, by comparison, ...

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

A Type 2 diabetes medication that can also aid in weight loss, GLP-1 scripts include the well-known names Ozempic and Wegovy. While discussing the use, safety and efficacy of GLP-1 drugs with Dr ...